Open AccessASO Author Reflections: Indolent Growth and Small Bowel Neuroendocrine Tumor Management
Author(s) -
Scott K. Sherman,
Catherine Tran,
James R. Howe
Publication year - 2021
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-021-09641-4
Subject(s) - medicine , surgical oncology , asymptomatic , referral , randomized controlled trial , general surgery , neuroendocrine tumors , incidence (geometry) , surgery , family medicine , physics , optics
Surgical treatment is central to management of small bowel neuroendocrine tumors (SBNETs). Current controversies include whether to resect asymptomatic primary tumors in the setting of unresectable metastases, the role of minimally invasive surgery, and how best to incorporate/sequence medical treatments. Low SBNET incidence, long event-times, and variability in disease burden, surgical technique, and institutional treatment preferences remain obstacles to conducting randomized surgical trials for SBNETs. With increasing referral of these patients to high-volume centers, cooperation between experienced SBNET clinicians should allow design of high-quality randomized trials to test new treatments and answer key questions.